Journal of Clinical Pediatrics >
Salvage therapy for refractory macrophage activation syndrome associated with systemic juvenile idiopathic arthritis: a case report
Received date: 2024-03-19
Accepted date: 2024-07-01
Online published: 2025-02-27
Objective The pursuit of salvage treatment for refractory macrophage activation syndrome (MAS) associated with systemic juvenile idiopathic arthritis (sJIA) is of paramount importance. This paper aims to investigate the application options and therapeutic efficacy of ruxolitinib in the treatment of refractory sJIA-MAS. Methods A retrospective analysis was performed on the clinical data of a child with refractory sJIA-MAS and the outcome following the administration of ruxolitinib. Results An 11-year-old girl, diagnosed with sJIA for four years and having experienced two previous episodes of MAS, was admitted to the hospital due to active sJIA and developed MAS again during the treatment course. Despite three rounds of high-dose methylprednisolone pulse therapy in combination with cyclosporine A and tocilizumab (TCZ), her condition failed to improve, with persistent high fever and severe liver function impairment, among other abnormal laboratory indicators. After discontinuing TCZ and initiating ruxolitinib with an adjusted oral dose of 10 mg twice daily, the child's condition improved, enabling a smooth reduction of the hormone dosage. Ruxolitinib was discontinued after approximately three months of treatment, and there was no recurrence of the disease. Conclusion Ruxolitinib may potentially serve as a salvage treatment option for refractory sJIA-MAS.
WU Jianqiang , SHEN Danping , LU Meiping . Salvage therapy for refractory macrophage activation syndrome associated with systemic juvenile idiopathic arthritis: a case report[J]. Journal of Clinical Pediatrics, 2025 , 43(3) : 216 -219 . DOI: 10.12372/jcp.2025.24e0236
[1] | Crayne CB, Albeituni S, Nichols KE, et al. The immunology of macrophage activation syndrome[J]. Front Immunol, 2019, 10: 119. |
[2] | Eloseily EM, Weiser P, Crayne CB, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis[J]. Arthritis Rheumatol, 2020, 72(2): 326-334. |
[3] | Wu J, Sun L, Tang X, et al. Effective therapy of tocilizumab on systemic juvenile idiopathic arthritis-associated refractory macrophage activation syndrome[J]. Mod Rheumatol, 2022, 32(6): 1114-1121. |
[4] | Onel KB, Horton DB, Lovell DJ, et al. 2021 American college of rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis[J]. Arthritis Care Res (Hoboken), 2022, 74(4): 521-537. |
[5] | Wang J, Wang Y, Wu L, et al. Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis[J]. Haematologica, 2020, 105(5): e210-e212. |
[6] | Zhang Q, Zhao YZ, Ma HH, et al. A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis[J]. Blood, 2022, 139(24): 3493-3504. |
[7] | Levy O, Apel A, Alhdor H, et al. Ruxolitinib for refractory macrophage activation syndrome complicating adult-onset still's disease[J]. Eur J Rheumatol, 2022, 9(4): 217-220. |
[8] | Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, edmonton, 2001[J]. J Rheumatol, 2004, 31(2): 390-392. |
[9] | Schulert GS, Minoia F, Bohnsack J, et al. Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis[J]. Arthritis Care Res (Hoboken), 2018, 70(3): 409-419. |
[10] | Shimizu M, Mizuta M, Okamoto N, et al. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis[J]. Pediatr Rheumatol Online J, 2020, 18(1): 2. |
[11] | Saper VE, Ombrello MJ, Tremoulet AH, et al. Severe delayed hypersensitivity reactions to Il-1 and Il-6 inhibitors link to common Hla-Drb1*15 alleles[J]. Ann Rheum Dis, 2022, 81(3): 406-415. |
[12] | Fu Y, Li J, Xu A, et al. Ruxolitinib rescued the macrophage activation syndrome in adult-onset still's disease with delayed hypersensitivity reaction to tocilizumab[J]. Rheumatology (Oxford), 2023, 62(7): e223-e225. |
[13] | Gillard L, Pouchot J, Cohen-Aubart F, et al. Jak Inhibitors in difficult-to-treat adult-onset still's disease and systemic-onset juvenile idiopathic arthritis[J]. Rheumatology (Oxford), 2023, 62(4): 1594-1604. |
[14] | He T, Xia Y, Luo Y, et al. Jak Inhibitors in systemic juvenile idiopathic arthritis[J]. Front Pediatr, 2023, 11: 1134312. |
[15] | Song Y, Li X, He X, et al. Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis[J]. Front Immunol, 2023, 14: 1211655. |
/
〈 |
|
〉 |